Goldman Sachs Said Pfizer (PFE) Best Positioned US Pharma in China
More News related to PFE
- Active equity option families in first 30 minutes: PFE, BAC, CSCO, AMZN, AAPL
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- Top 10 News Items 2/1-2/5: 9.7% Unemployment Rate Surprises the Market, Dow Breaks 10,000, But Recovers, Troubles at Toyota Continue
- Active equity option families in first 30 minutes: BAC F PFE AAPL
- QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
More News related to Analyst Comments
- Analyst Positive On JP Morgan (JPM) Following Recent Correction
- UBS Maintains a 'Neutral' on Charles River (CRL); Updates Estimates
- UBS Maintains a 'Neutral' on Parkway Properties (PKY); Adjusts Estimates & PT
- UBS Maintains a 'Buy' on Molson Coors (TAP), Lowers PT
- UBS Maintains a 'Buy' on Martin Marietta Materials (MLM); Delayed Rebound, But Remains Intact
Goldman Sachs reiterated their Conviction Buy List rating and $22 price target on Pfizer (NYSE: PFE) after their China healthcare tour. The firm said Pfizer is the best positioned of the US pharma companies as it is ranked #1 in China and #2 in EGMs.
The firm said Pfizer's EGM sales could add an incremental $3.5 billion to its top line by 2012, of which China alone could contribute $2.0 billion.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
-0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
